Clinicopathologic characteristics and survival rate in patients with synchronous or metachronous double primary colorectal and gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ji-Hyeon Park | - |
dc.contributor.author | 백정흠 | - |
dc.contributor.author | Jun-Young Yang | - |
dc.contributor.author | Won-Suk Lee | - |
dc.contributor.author | Woon Kee Lee | - |
dc.date.available | 2020-02-27T13:42:02Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2018-12 | - |
dc.identifier.issn | 1738-8082 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/4587 | - |
dc.description.abstract | Purpose: Double primary colorectal cancer (CRC) and gastric cancer (GC) represent the most common multiple primary malignant tumors (MPMT) in Korea. The recognition and screening of hidden malignancies other than the primary cancer are critical. This study aimed to inves�tigate the clinicopathologic characteristics and survival rates in patients with synchronous or metachronous double primary CRC and GC. Methods: Between January 1994 and May 2018, 11,050 patients were diagnosed with CRC (n=5,454) or GC (n=5,596) at Gil Medical Cen�ter. MPMT and metastatic malignant tumors were excluded from this study. A total of 103 patients with double primary CRC and GC were divided into two groups: the synchronous group (n=40) and the metachronous group (n=63). The incidence, clinicopathologic characteris�tics, and survival rate of the two groups were analyzed. Results: The incidence of synchronous and metachronous double primary CRC and GC was 0.93%. Double primary CRC and GC commonly occurred in male patients aged over 60 years with low comorbidities and minimal previous cancer history. There were significant differences between the synchronous and metachronous groups in terms of age, morbidity, and overall survival. Metachronous group patients were 6 years younger on average (P=0.009), had low comorbidities (P=0.008), and showed a higher 5-year overall survival rate (94.8% and 61.3%, P<0.001) in contrast to synchronous group. Conclusion: When primary cancer (CRC or GC) is detected, it is important to be aware of the possibility of the second primary cancer (GC or CRC) development at that time or during follow-up to achieve early detection and better prognosis. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한종양외과학회 | - |
dc.relation.isPartOf | 대한종양외과학회지 | - |
dc.title | Clinicopathologic characteristics and survival rate in patients with synchronous or metachronous double primary colorectal and gastric cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.doi | 10.14216/kjco.18015 | - |
dc.identifier.bibliographicCitation | 대한종양외과학회지, v.14, no.2, pp.83 - 88 | - |
dc.identifier.kciid | ART002426690 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 88 | - |
dc.citation.startPage | 83 | - |
dc.citation.title | 대한종양외과학회지 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Ji-Hyeon Park | - |
dc.contributor.affiliatedAuthor | 백정흠 | - |
dc.contributor.affiliatedAuthor | Jun-Young Yang | - |
dc.contributor.affiliatedAuthor | Won-Suk Lee | - |
dc.contributor.affiliatedAuthor | Woon Kee Lee | - |
dc.subject.keywordAuthor | Multiple primary neoplasms | - |
dc.subject.keywordAuthor | Second primary neoplasm | - |
dc.subject.keywordAuthor | Colorectal neoplasm | - |
dc.subject.keywordAuthor | Stomach neoplasm | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.